Glaucoma Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 6.40 Billion |
| Market Size (2029) | USD 8.02 Billion |
| CAGR (2024 - 2029) | 4.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Glaucoma Treatment Market Analysis
The Glaucoma Treatment Market size is estimated at USD 6.40 billion in 2024, and is expected to reach USD 8.02 billion by 2029, growing at a CAGR of 4.60% during the forecast period (2024-2029).
The major factors for the growth of the glaucoma treatment market include the increasing prevalence of glaucoma, rising initiatives to increase awareness about glaucoma, and technological advancements in the field of ophthalmology.
Glaucoma is the second leading cause of blindness, globally. This generally happens due to raised intraocular tension. The main therapeutic goal is to lower the intraocular tension. This is done either by reducing the secretion of aqueous humor or increasing its drainage. Glaucoma has also been divided into an open angle (wide angle), chronic glaucoma and angle-closure (narrow-angle), and acute congestive glaucoma. Although the drugs of glaucoma reduce the symptoms, there is no complete cure for this condition. The drugs used for the treatment of glaucoma are segmented into beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogs, and combination medications.
According to WHO estimates, more than 60 million patients are suffering from glaucoma worldwide, as per 2019 statistics. According to the Glaucoma Research Foundation, in the United States, more than 120,000 patients are blind from glaucoma. Thus, owing to the rising cases of glaucoma the market is expected to witness high growth over the forecast period.
Glaucoma Treatment Market Trends
Prostaglandin Analogs is the Segment by Drug Class that is Expected to Witness Fastest Growth Over the Forecast Period
Prostaglandin analogs work by increasing the outflow of intraocular fluid from the eye. They have few systemic side effects but are associated with changes to the eye itself, including change in iris color and growth of eyelashes. Depending on the individual, one brand of this type of medication may be more effective and produce fewer side effects.
Prostaglandin analogs are taken as eye drops. They are effective at reducing intraocular pressure in people who have open-angle glaucoma. Latanoprost and some formulations of bimatoprost and travoprost are now available in generic form. Tafluprost is a preservative-free prostaglandin analog.
The demand for these drugs is expected to rise as the incidence of glaucoma has increased over the past few years due to the aging population. Moreover, the incidence of the disease is expected to increase in the future as the population aged 60 years and over are expected to increase from 12.7% in 2017 to 21.3% by 2050, as per a 2017 report by the United Nations. Increasing geriatric population is expected to increase the prevalence of glaucoma, as the disaese is more prevalent in the elderly. Hence the demand for Prostaglandin Analogs is also expected to increase, which will boost the market growth.
North America is Expected to Hold Largest Market Share over the Forecast Period
The United States is expected to be the largest glaucoma treatment market owing to the rising cases of glaucoma and the presence of better healthcare infrastructure. As per the data published by the BrightFocus Foundation more than 3 million Americans are living with glaucoma and open-angle glaucoma is the most common form of glaucoma.
Furthermore, glaucoma costs to the United States economy around USD 2.86 billion every year in direct costs and productivity losses. Also, there are various organizations in the United States creating awareness regarding glaucoma which is expected to propel the overall growth of the market.
Glaucoma Treatment Industry Overview
The market studied is a consolidated market owing to the presence of few major market players. Some of the market players are AERIE PHARMACEUTICALS, INC., Akorn, Incorporated, Allergan Plc, Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc, and Santen Pharmaceutical Co., Ltd.
Glaucoma Treatment Market Leaders
-
AERIE PHARMACEUTICALS, INC.
-
Akorn, Incorporated
-
Allergan Plc
-
Bausch & Lomb Incorporated
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Glaucoma Treatment Market News
- In January 2024, Indiana University School of Medicine researchers adopted an innovative strategy in their quest to craft a novel therapy for glaucoma, a progressive ailment culminating in blindness. This initiative is bolstered by a recent USD 2 million R01 grant from the National Eye Institute, spanning five years.
- In December 2023, Glaukos Corporation received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, which is indicated for reducing intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).
Glaucoma Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Glaucoma
4.2.2 Rising Initiatives to Increase Awareness about the Glaucoma
4.2.3 Technological Advancements in the Field of Ophthalmology
4.3 Market Restraints
4.3.1 Side Effects associated with the Products
4.3.2 Stringent Approval Process
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Indication
5.1.1 Open Angle Glaucoma
5.1.2 Closed Angle Glaucoma
5.1.3 Secondary Glaucoma
5.1.4 Congenital Glaucoma
5.1.5 Others
5.2 By Drug Class
5.2.1 Prostaglandin Analogs
5.2.2 Beta Blockers
5.2.3 Alpha Agonist
5.2.4 Carbonic Anhydrase Inhibitors
5.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aerie Pharmaceuticals Inc.
6.1.2 Akorn, Incorporated
6.1.3 Abbvie Inc. (Allergan Plc)
6.1.4 Bausch Health (Bausch & Lomb Incorporated)
6.1.5 Inotek Pharmaceuticals
6.1.6 Merck & Co., Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc
6.1.9 Santen Pharmaceutical Co., Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Glaucoma Treatment Industry Segmentation
As per the scope of this report, glaucoma treatment market covers the drugs used to reduce the secretion of aqueous humor or increasing its drainage. The market is segmented by indication, drug class, and geography.
| By Indication | |
| Open Angle Glaucoma | |
| Closed Angle Glaucoma | |
| Secondary Glaucoma | |
| Congenital Glaucoma | |
| Others |
| By Drug Class | |
| Prostaglandin Analogs | |
| Beta Blockers | |
| Alpha Agonist | |
| Carbonic Anhydrase Inhibitors | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Glaucoma Treatment Market Research FAQs
How big is the Glaucoma Treatment Market?
The Glaucoma Treatment Market size is expected to reach USD 6.40 billion in 2024 and grow at a CAGR of 4.60% to reach USD 8.02 billion by 2029.
What is the current Glaucoma Treatment Market size?
In 2024, the Glaucoma Treatment Market size is expected to reach USD 6.40 billion.
Who are the key players in Glaucoma Treatment Market?
AERIE PHARMACEUTICALS, INC., Akorn, Incorporated, Allergan Plc, Bausch & Lomb Incorporated and Novartis AG are the major companies operating in the Glaucoma Treatment Market.
Which is the fastest growing region in Glaucoma Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Glaucoma Treatment Market?
In 2024, the North America accounts for the largest market share in Glaucoma Treatment Market.
What years does this Glaucoma Treatment Market cover, and what was the market size in 2023?
In 2023, the Glaucoma Treatment Market size was estimated at USD 6.11 billion. The report covers the Glaucoma Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Glaucoma Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Glaucoma Treatment Industry Report
Statistics for the 2024 Glaucoma Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Glaucoma Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
